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Abstract
Background: Umbelliferone, also known as 7-hydroxycoumarin, is a phenolic metabolite found in many familiar
plants. Its derivatives have been shown to have various pharmacological and chemo-preventive effects on human
health. A uridine diphosphate glycosyltransferase YjiC from Bacillus licheniformis DSM 13, a cytochrome P450BM3
(CYP450 BM3) variant namely mutant 13 (M13) from Bacillus megaterium, and an O-methyltransferase from
Streptomyces avermitilis (SaOMT2) were used for modifications of umbelliferone.
Results: Three umbelliferone derivatives (esculetin, skimmin, and herniarin) were generated through enzymatic and
whole cell catalysis. To improve the efficiencies of biotransformation, different media, incubation time and concentration
of substrate were optimized and the production was scaled up using a 3-L fermentor. The maximum yields of esculetin,
skimmin, and herniarin were 337.10 μM (67.62%), 995.43 μM (99.54%), and 37.13 μM (37.13%), respectively. The water
solubility of esculetin and skimmin were 1.28-folds and 3.98-folds as high as umbelliferone, respectively, whereas
herniarin was 1.89-folds less soluble than umbelliferone. Moreover, the antibacterial and anticancer activities of herniarin
showed higher than umbelliferone, esculetin and skimmin.
Conclusions: This study proves that both native and engineered enzymes could be employed for the production of
precious compounds via whole cell biocatalysis. We successfully produced three molecules herniarin, esculetin and
skimmin in practical amounts and their antibacterial and anticancer properties were accessed. One of the newly
synthesized molecules the present research suggests that the combinatorial biosynthesis of different biosynthetic
enzymes could rapidly promote to a novel secondary metabolite.
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Background
Umbelliferone and its derivatives are compounds derived
from coumarin (Fig. 1) with pharmacological and che-
mopreventive benefits for human health. Umbelliferone
is known to have antinociceptive and anti-inflammatory
activities in animal models [1]. Moreover, esculetin ex-
hibits various biological activities including antioxidant
[2], anti-tumor, anti-metastatic [3], anti-proliferative, pro-
apoptotic [4], and neuroprotective activities [5]. Umbelli-
ferone glycosides have been found to possess neuroprotec-
tive effects against serum deprivation-induced PC12 cell
damage [6] with antidiabetic, antihyperlipidemic, and anti-
oxidative activities [7]. Furthermore, 7-methoxycoumarin
showed antifugal and antibacterial activities [8]. Likewise,
other umbelliferone derivatives such as scopoletin, scopar-
one, fraxetin, esculin, and daphnetin have been reported
to have antioxidant and intestinal anti-inflammatory
activities [9].
Coumarins are phenolic metabolites commonly distrib-
uted in many plant species [10]. The ortho-hydroxylation
of cinnamate is a pivotal step in the biosynthesis of
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coumarin in plants. The core structure, 2H-1-benzopyran-
2-one, of umbelliferone and its derivatives are formed via
ortho-hydroxylation of cinnamates which undergo trans/
cis isomerization of the side-chain followed by lactoni-
zation [11]. Although these compounds exhibit multi-
beneficial pharmacological properties, isolation and
purification of umbelliferone and its derivatives from
plants are problematic due to low concentration and
seasonal and regional dependency [12]. On the other
hand, chemical synthesis requires the usage of hazard-
ous agents, long synthetic steps, and extreme reaction
conditions [13, 14].
Recently, an alternative approach has emerged as a
promising method to synthesize small molecules by en-
gineering microbes. Simple coumarins have been obtained
from engineered Escherichia coli (E. coli) by combinational
expression of artificial pathway enzymes with diverse gen-
etic source including phenylalanine ammonia lyase (PAL)
or tyrosine ammonia lyase (TAL), 4-cinnamic acid:coen-
zyme A ligase (4CL), coumarin synthase (C2´H,
coumaroyl-CoA 2′-hydroxylase; or F6´H, feruloyl-CoA 6′-
hydroxylase) [15–17]. For example, umbelliferone and sco-
poletin have been synthesized by using TAL, HpaBC (4-
hydroxyphenylacetate 3-hydroxylase), and CCoAOMT (caf-
feoyl-CoA O-methyltransferase) in conjunction with 4CL
and F6´H from p-coumaric acid and ferulic acid, respect-
ively [16]. Moreover, tyrosine can be converted to esculetin
by employing TAL, C3H (coumarate 3-hydroxylase from
E.coli) or Sam5 (a monooxygenase from Saccharothrix
espanaensis), 4CL, and F6´H [17, 18]. These researches
demonstrated that hydroxyl cinnamic acid or glucose was
the strating material for biosynthesis of simple coumarins.
However, low catalytic activity, low final yield, and limited
products are the most frequently encountered problems
when applying a combinatorial expression approach.
In this study, biocatalyst system was carried out to mod-
ify umbelliferone by using glycosyltransferase, cytochrome
P450, and O-methyltransferase. Three derivatives of
umbelliferone, namely esculetin, skimmin, and herniarin,
were successfully synthesized and their antibacterial and
anticancer activities were evaluated.
Results
Protein expression and purification
Recombinant proteins CYP450 BM3 (119 kDa), M13
(119 kDa), YjiC (45 kDa), and SaOMT2 (37.5 kDa) were
overexpressed in E. coli BL21 (DE3) (Additional file 1: Fig-
ure S1). The content acquired from the soluble fractions of
proteins CYP450 BM3 and M13 were 477.253 and
1932.069 nM/L, respectively. The concentrations of crude
proteins of CYP450 BM3, M13, YjiC, and SaOMT2 were
determined to be approximately 147.54, 122.93, 344.28,
and 76.99 μg/mL, respectively, based on the Bradford
method.
Enzymatic reaction
The four enzymes was performed enzymatic reaction using
umbelliferone as standard substrate. The results were
analyzed by high performance liquid chromatography-
photodiode array (HPLC-PDA) and high-resolution
quadruple time-of-flight electrospray ionization-mass
spectrometry (HR-QTOF ESI/MS). The retention time
(tR) of umbelliferone standard was observed at 13.749 min
with UV absorbance at 330 nm (Fig. 2a(i)). The found mass
of umbelliferone was ~ 163.0394 [M+H]+ m/z+ equivalent
to molecular formula C9H7O3, for which the calculated
mass was 163.0395 (Additional file 1: Figure S2A). HPLC-
PDA chromatogram revealed the appearance of a new peak
(P1) in the hydroxylation reaction of both CYP450 BM3
and M13. A new peak tR at 12.730 min (Fig. 2a(ii;iii))
and λmax at 325 nm might be hydroxylated umbellifer-
one. P1 was further analyzed by HR-QTOF ESI/MS.
The mass spectrum displayed a peak with found mass
of ∼ 179.0390 [M + H]+ m/z+, resembling the mass of
mono-hydroxylated derivative of umbelliferone with a
molecular formula C9H7O4, for which the calculated
Fig. 1 The chemical structure of the simple coumarins
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mass was ∼ 179.0344 (Additional file 1: Figure S2B).
HPLC-PDA analysis showed that M13 had higher cata-
lytic activity (35.48%) as a monooxygenase than
CYP450 BM3 in which the conversion was limited to
8.29% (Table 1, Fig. 2a(iii)). Moreover, the HPLC-PDA
analysis of glycosylation reaction mixture showed a new
peak at tR of 10.323 min (P2) (Fig. 2a(iv)). P2 exhibited
the found mass [M + H]+ m/z+ at ~ 325.0912 with
λmax:317 nm, corresponding to the calculated mass of
the mono-glucoside derivative of umbelliferone with
molecular formula C15H17O8 for [M + H]
+ m/z+ ~
325.0923 (Additional file 1: Figure S2C). Furthermore,
the HPLC-PDA analysis of methylation reaction mix-
ture exhibited an additional peak at at tR of 16.381 min
(P3) (Fig. 2a(v)). P3 showed the exact mass [M + H]+
m/z+ at ~ 177.0553 with λmax:321 nm, corresponding to
the calculated mass of methylated umbelliferone with
molecular formula C10H9O3 for [M + H]
+ m/z+ ~
177.0552 (Additional file 1: Figure S2D). The result dis-
played the conversion of umbelliferone to its derivatives
were 86.45% and 2.08% in the glycosylation and methy-
lation reactions, respectively (Table 1). These in vitro
results indicated that umbelliferone might be a substrate
of various transferase enzymes. It was converted more
efficiently to glycosylated form than other derivatives.
Therefore, umbelliferone was used for the production
of its derivatives by using M13, YjiC, and SaOMT2 in
whole cells.
Fig. 2 a In vitro reaction mixture and b whole cells bioconversion of umbelliferone on the HPLC-PDA analysis. (i) control reaction of umbelliferone
using E. coli BL21 (DE3); (ii) hydroxylation with M13 and (iii) CYP450 BM3 at 48 h; (iv) glycosylation with YjiC at 12 h; and (v) methylation with SaOMT2
at 48 h, respectively
Table 1 The HPLC-PDA, chemical formula, HR-QTOF ESI/MS, UV maxima and conversion product analyses of umbelliferone in in vitro
reaction using CYP450 BM3 and its variant proteins M13, YjiC and SaOMT2
Name HPLC (tR) min Chemical formula Calculated mass
[M + H]+ m/z+~
Exact mass
[M + H]+ m/z+~
UV maxima (nm) % Conversion
Substrate Umbelliferone 13.749 C9H6O3 163.0395 163.0394 327
Products Hydroxylated (P1)
by P450 BM3




Glycosylated (P2) 10.323 C15H16O8 325.0923 325.0912 317 86.45
Methylated (P3) 16.381 C10H8O3 177.0344 177.0547 321 2.08
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Bioconversion of umbelliferone using CYP450 BM3 and
its variant
The hydroxylated derivative was produced from umbelli-
ferone by using E. coli harboring pCW(Ori+)-CYP450
BM3 wild type and E. coli harboring pCW(Ori+)-mutant
13 (M13). The cells were induced with IPTG and were
incubated at 28 °C with 100 μM umbelliferone for 12 h
in various media as described in materials and methods.
Culture media and cell pellets were extracted with ethyl
acetate (EtOAc) and the products were analyzed by
HPLC-PDA. HPLC-PDA chromatograms of both strains
showed a new peak at tR ~ 12.730 min (P1) in comparison
with umbelliferone standard at tR ~ 13.749 min under UV
absorbance of 330 nm (Fig. 2b(i; ii)). All detected peaks
were further analyzed by HR-QTOF ESI/MS. The
found mass of umbelliferone standard was observed at ∼
163.0394 [M+H]+ m/z+ corresponding to molecular for-
mula C9H7O3 with λmax ∼ 327 nm, for which the calcu-
lated mass was ∼ 163.0395 (Additional file 1: Figure S2A).
The found mass of hydroxylated product P1 at ∼ 179.0390
[M + H]+ m/z+ corresponding to molecular formula
C9H7O4 with λmax ∼ 325 nm, for which the calculated
mass was ∼ 179.0344 (Additional file 1: Figure S2B).
The bioconversion rate of umbelliferone to hydroxylated
products was very low with the wild type strain using
all three different media. However, the conversion was
relatively higher with E. coli BL21(DE3) harboring
pCW(Ori+)-mutant 13 (M13). The highest hydroxylated
product was recorded to be 84.70 μM (84.7% conver-
sion) in M9 medium, which was 1.85-fold higher than
that in Luria-Bertani (LB) medium (45.72 μM) and
2.07-fold higher than that in Terrific Broth (TB) medium
(40.84 μM) (Additional file 1: Figure S3A). These results
further mean that M9 medium was a suitable medium for
the production of hydroxylated product from umbelli-
ferone. Similar trend has been observed with other fla-
vonoid molecules [19]. However, the exact reason
behind this is unclear. After that, E. coli BL21(DE3) har-
boring pCW(Ori+)-mutant 13 was chosen to optimize the
substrate conversion with separately supplied 100, 250,
500, 750, and 1000 μM of umbelliferone. Substrate
utilization and cell growth were measured at 12 h inter-
vals. The maximum concentration of hydroxylated prod-
uct was 329.29 μM (65.86%) at 48 h with OD600 ~ 3.949
when 500 μM of umbelliferone was added into the bio-
transformation reaction. Even though umbelliferone was
non-toxic to cells (Additional file 1: Figure S3B), biocon-
version was inhibited when a higher amount of substrate
was supplied (Additional file 1: Figure S3C). Recombinant
strain E. coli BL21(DE3) harboring pCW(Ori+)-mutant
13 were cultured in a 3-L fermentor with 1 × M9 min-
imal medium supplemented with 500 μM umbelliferone
(~243.2 mg in 3-L) and supplied 2% glucose. The
temperature and pH of the fermentor were kept
constant at 28 °C and 7.6, respectively. The samples
were taken at 12 h interval and measured by HPLC-
PDA. Only 377.0959 μM (~180.2 mg; 60.1 mg/L) of hy-
droxylated umbelliferone was produced until 48 h as
the maximal yield with bioconversion rate of the sub-
strate at OD600 nm ~ 43.37 of approximately 67.62%
(Fig. 3a).
Production of glucosylated umbelliferone
The glucosylated derivative was synthesized from umbel-
liferone by using E.coli harboring pET28a-YjiC. This E.
coli strain was fed with 100 μM substrate at 20 °C for
12 h in various media. The product was extracted with
twice volume of EtOAc. HPLC-PDA analysis showed a
new peak (P2) with tR ~ 10.323 min compared to tR ~
Fig. 3 The scale-up of a hydroxylated b glucosylated c methylated
umbelliferone and cell growth at OD600 nm in 3-L fermentation at
different time intervals
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13.749 min of a substrate under UV absorbance of
330 nm (Fig. 2b(i; iii)). The found mass of glycosylated
product P2 [M +H]+ m/z+ was ∼ 325.0912, resembling
molecular formula C15H17O8 with λmax ∼ 317 nm. The
calculated mass was ∼ 325.0923 (Additional file 1: Figure
S2C). While the highest bioconversion of umbelliferone
to glucosylated derivative was observed in M9 medium
(99.65 μM, 99.65%), which was lower in both LB
(58.70 μM, 58.70%) and TB (46.91 μM, 46.91%) media
under identical reaction conditions. (Additional file 1:
Figure S4A). The different concentration of umbellifer-
one (100, 500, 1000, 1500 and 2000 μM) was fed into
the culture of E.coli harboring pET28a-YjiC in the M9
1x medium. An equal volume of sample was taken and
analyzed at 3 h intervals. Time and concentration
dependent study showed that the highest concentration
of umbelliferone glucoside was 996.72 μM (99.67%) with
OD600 ~ 3.06 at 12 h when 1000 μM of substrate was
supplemented in the culture. Umbelliferone failed to
affect the growth rate of cells (Additional file 1: Figure
S4B). However, the amount of glycosylated product was
not significantly increased when a higher amount of sub-
strate was supplied (Additional file 1: Figure S4C).
Therefore, 1000 μM umbelliferone and 1x M9 minimal
medium with 2% glucose were selected for the scale up
of bioconversion reaction in 3-L fermentor. Nearly all
umbelliferone was transformed into glycosylated product
at 6 h, yielding approximately 995.43 μM (~967.6 mg;
322.8 mg/L) of product with OD600 nm ~ 22.7 (Fig. 3b).
Whole cell methylation of umbelliferone
E. coli harboring pRSF-Duet-SaOMT2 was subjected to
methylation process of umbelliferone. The biotransform-
ation system was supplied with 100 μM and incubated at
20 °C for 48 h in various media. The product was ex-
tracted with EtOAc and analyzed by HPLC-PDA. The
result showed methylation product of substrate with a
peak at tR ~ 16.381 min whereas the aglycone moiety of
umbelliferone appeared at tR ~ 13.749 min (Fig. 2b(iv)).
Subsequently, the peak at tR ~ 16.381 min was further
analyzed by HR-QTOF ESI/MS. The observed mass
[M + H]+ m/z+ was ∼ 177.0553, resembling molecular
formula C10H19O3 with λmax ∼ 321 nm. The calculated
mass of methylated umbelliferone was ∼ 177.0552
(Additional file 1: Figure S2D).
Unlike hydroxylation and glycosylation reactions in
whole cell biotransformation, methylated product was
produced at maximum concentration (17.61 μM, 17.61%
conversion) after 48 h incubation in LB media, followed
by that in M9 (2.60 μM, 2.6%) and TB media (1.15 μM,
1.15%) (Additional file 1: Figure S5A). The results of op-
timized conversion showed that the maximum concen-
tration of methylated product was 17.61 μM (17.61%) at
48 h with OD600 ~ 3.45 when 100 μM of umbelliferone
was added into the biotransformation reaction (Add-
itional file 1: Figure S5B). Umbelliferone did not affect
the growth rate of cells. However, the bioconversion
from a substrate to the methylated product was not
meaningfully increased when a higher amount of sub-
strate was supplied (Additional file 1: Figure S5C). To
test the reproducibility of the bioconversion process into
the large-scale fermentor, batch fermentation of this strain
was carried out in a 3-L fermentor with LB medium sup-
plied with umbelliferone at 100 μM (~48.64 mg in 3-L).
The temperature and pH of the fermentor were main-
tained at 25 °C and 7.6, respectively. The samples were
detached at 12 h interval and measured by HPLC-PDA.
HPLC-PDA analysis revealed that methylated product
bioconversion was increased to 37.13 μM (~19.6 mg;
6.5 mg/L) at 48 h with OD600 nm ~ 39.21 (Fig. 3c).
Structural elucidation of umbelliferone and its derivatives
The structures of umbelliferone standard and purified
modified products were analyzed by proton nuclear
magnetic resonance (1H-NMR) and carbon-13 nuclear
magnetic resonance (13C-NMR) at 700 MHz in dimethyl
sulfoxide-d6 (DMSO-d6). We re-confirmed umbelliferone
based on the previous report (Additional file 1: Figure S6)
[20]. The 1H-NMR spectrum of hydroxylated umbellifer-
one showed the absence of proton signal at δ = 6.79 ppm
(J = 8.4, 2.3 Hz) for C-6. It showed the presence of a new
signal at δ = 10.09 ppm (s) for a hydroxyl group. An up-
field shift at δ = 139.02 ppm of the C-6 of hydroxylated
product was also observed in comparison with the same
carbon of umbelliferone at δ = 113.59 ppm accompanied
with a downfield shift of the resonances of adjacent car-
bons C-7 at δ = 158.21 ppm and δ = 160.92 ppm, respect-
ively (Table 2; Additional file 1: Figure S7). Furthermore,
the compound was identical to an authentic sample of es-
culetin, a hydroxylated derivative of umbelliferone [21].
In addition, 1H-NMR study of the purified glycosylated
product displayed the presence of an anomeric proton at
δ = 5.03 ppm (d, J = 7.5 Hz, H-1´) with a beta (β) config-
uration of the sugar moiety, whereas the sugar region
observed between δ of 3.13 and 4.28 ppm. In 13C-NMR,
6 carbon signals of the O-glucoside moiety were found
at δ = 100.43 (C-1´), δ = 73.52 (C-2´), δ = 77.57 (C-3´), δ
= 70.03 (C-4´), δ = 76.85 (C-5´), and δ = 61.05 ppm (C-
6´) (Table 2; Additional file 1: Figure S8A&B). The site
of glycosylation at C-7 was confirmed by a correlation
between the anomeric proton H-1’ at δ = 5.03 ppm and
carbon C-7 at δ = 160.68 ppm of umbelliferone in Hetero-
nuclear multiple-bond correlation spectroscopy (HMBC)
analysis (Additional file 1: Figure S8C). These analyses
identified that the glycosylated product was 7-O-β-D glu-
copyranosyl umbelliferone, also known as skimmin [22].
Moreover, the 1H-NMR spectrum of the purified meth-
ylated product showed a set of signal at δ = 3.86 ppm
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(s, 3H) corresponding to a methyl group. Furthermore,
the 13C-NMR showed ten carbons signals, including
one new methyl group at δ = 56.42 ppm representing
O-CH3 group in comparison with the nine carbon sig-
nals of umbelliferone (Table 2; Additional file 1: Figure
S9A&B). The site of methylation at C-7 was confirmed
by a correlation between methyl group and carbon C-7
at δ = 162.95 ppm of umbelliferone in HMBC analysis
(Additional file 1: Figure S9C). These data confirmed
that methylated product was 7-methoxycoumarin, also
known as herniarin [21].
Water solubility determination
The data showed that the water solubility of herniarin was
decreased by 1.89-folds, whereas esculetin and skimmin
were significantly improved by 1.28 and 3.98-folds, re-
spectively, compared to that of umbelliferone. These re-
sults indicated that hydroxylation and glycosylation of
umbelliferone enhanced its water solubility by attachment
of hydrophilic moieties, while methylation decreased its
water solubility by attachment of hydrophobic methyl
moiety.
Antibacterial activities
Results of disc diffusion assays showed that umbelliferone,
esculetin, and skimmin did not exhibit any antibacterial
activity against the tested five different human pathogens
when 10 μL of 100 mM compound was applied. How-
ever, herniarin exhibited antibacterial activity against
Gram-positive bacteria Staphylococcus aureus subsp.
aureus KCTC 1916 (S. aureus) and Bacillus subtilis
KACC 17047 (B. subtilis) with a zone of inhibition
values of 9 ± 0.12 mm and 8.5 ± 0.18 mm, respectively
(Additional file 1: Table S1). These results revealed that
methylation of umbelliferone at hydroxyl group of the
C-7 position might be profitable for heightening its
antibacterial activity against Gram-positive bacteria.
Anticancer activities
All prepared compounds were further evaluated for their
in vitro cytotoxicity by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) colorimetric assay
against four different cancer cell lines (Fig. 4). Results
showed that herniarin exhibited good cytotoxic activities
compared to the other three compounds. Cell viability
of skin melanoma (B16F10), gastric carcinoma (AGS),
Table 2 Umbelliferone in comparision with hydroxylated (esculetin), glucosylated (skimmin) and methylated umbelliferone
(herniarin) on 1H-NMR and 13C-NMR analyses
Carbon No. Umbelliferone Esculetin Skimmin Herniarin
1H NMR 13C NMR 1H NMR 13C NMR 1H NMR 13C NMR 1H NMR 13C NMR
2 160.92 158.21 158.64 160.77
3 6.20 (d, J = 9.4 Hz). 111.87 6.70 (d, J = 2.3 Hz) 113.61 6.33 (d, J = 9.5 Hz) 113.75 6.30 (d, J = 9.4 Hz) 112.89
4 7.93 (d, J = 9.4 Hz) 145.00 7.35 (d, J = 8.4 Hz) 127.73 8.01 (d, J = 9.5 Hz) 144.74 8.00 (d, J = 9.5 Hz) 144.84
4a 111.75 112.72 113.61 101.19
5 7.52 (s) 130.18 7.06 (s) 116.69 7.65 (d, J = 8.6 Hz) 129.91 7.64 (d, J = 8.5 Hz) 129.97
6 6.79 (dd, J = 8.4, 2.3 Hz) 113.59 139.02 7.05 (d, J = 2.3 Hz) 114.13 6.96 (dd, J = 8.6, 2.4 Hz) 112.96
7 161.76 159.16 160.68 162.96
8 6.72 (s) 102.63 6.74 (dd, J = 8.5,
2.3 Hz)
102.36 7.02 (dd, J = 8.6, 2.3 Hz) 103.63 7.01 (d, J = 2.4 Hz) 75.85
8a 155.97 151.00 155.50 155.91
1’ 5.03 (d, J = 7.5 Hz) 100.43 56.42
2’ 3.44 (dd, J = 10.9, 6.1 Hz) 73.52
3’ 3.38 – 3.22 (m) 77.57
4’ 3.13 (s) 70.03
5’ 3.68 (dd, J = 2.9, 1.1 Hz) 76.85
6’ 4.28 (d, J = 9.1 Hz) 61.05
Hydroxyl group




s singlet, d doublet, dd doublet of doublet, m multiplet
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epitheliod cervix carcinoma (HeLa) and hepatic carcinoma
(HepG2) reduced approximately 32.63%, 20.25%, 12.79%,
and 31.28% (p < 0.05), respectively, compared to controls,
when treated 400 μM of herniarin. The 50% inhibitory
concentration (IC50) values of herniarin for B16F10,
AGS, HeLa and HepG2 cells were 197.0, 28.29, 80.21,
and 206.1 μM, respectively. Skimmin inhibited AGS cell
lines with an IC50 value of 34.42 μM. However, esculetin
did not show any activity against the tested cell lines,
whereas umbelliferone exhibited effective anticancer
activity against AGS and HepG2 cell lines with IC50
values of 129.9 and 222.3 μM, respectively (Additional
file 1: Table S2). These results suggest that herniarin
and skimmin can remarkable reduce the cell viability of
AGS cell line in a dose-dependent manner. This is the
first report of the activity of the two compounds against
AGS cell line.
Discussion
Post-modifications of natural compounds is one of the
approaches to enhance the biological and pharmaceutical
properties of parent molecules [23]. In this research, we
produced three umbelliferone derivatives using a monoox-
ygenase, a glycosyltransferase, and a methyltransferase en-
zyme via microbial biotransformation in E. coli. First,
umbelliferone was oxidized by CYP450 BM3 from B.
megaterium and its variant M13 to produce metabolite es-
culetin. Second, a flexible glycosyltransferase YjiC from B.
licheniformis capable of accepting various small molecules
such as chalcone [24, 25], flavonoids [26], stilbene [27],
and anthracycline antibiotic were used for efficient glyco-
sylation of umbelliferone to produce skimmin [28]. Finally,
we extended acceptor substrate of SaOMT2 from S. aver-
mitilis [29] to produce herniarin. Our results suggest that
modification of umbelliferone with different enzymes can
be used to develop new compounds with novel biological
activities.
Enzymatic methods were considerable contributed to
the industrial production of pharmaceutical substances
[30]. However, there are several shortcomings when utiliz-
ing an in vitro enzymatic synthesis approach. Most bioca-
talysts are limited by cofactor-dependent enzymes such as
CYP BM3 which is NADPH-dependent cytochrome P450
[31] and YjiC, a UDP-dependent glycosyltransferase. In
addition, NADPH, UDP-glucose, and S-adenosyl-L-
methionine (SAM) not only are high cost but also un-
stable to limit their apply in small scale stoichiometric
reaction [32]. Although alternative cofactors-generating
systems have been developed for large-scale reactions, the
cost of reaction is still too expensive and reaction yield is
deficient [33]. For example, only 8.09% and 35.48% of con-
version rates from umbelliferone to esculetin were found
in in vitro reactions with CYP450 BM3 and M13, respect-
ively. Similarly, methylation reaction of SaOMT2 are lim-
ited convert substrate to herniarin (Table 1). Therefore,
metabolic engineering and microbial biotransformation
approaches are needed to further enhance the production
by utilizing indigenous co-factors, ultimately lowering the
cost of target molecule production.
Interestingly, the catalytic efficiency of M13 with
umbelliferone was 4.39-folds higher than CYP450 BM3
in in vitro reaction. In addition, protein M13 showed
higher catalytic efficiency for umbellifferone than wild-
type CYP450 BM3 in whole cells for 48 h under the
Fig. 4 The growth of four cancer cell lines were treated with umbelliferone and its derivatives
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same condition (Table 2; Additional file 1: Figure S3).
The long-distance between the heme iron at ferric rest-
ing state in the CYP450 BM3 and oxidizable carbon of
umbelliferone is one of the reasons for the low biocon-
version efficiency [34]. Furthermore, substitution of sev-
eral key amino acids in the wild-type protein can affect
on the activity and selectivity of the biocatalyst reaction.
For example, arginine residues at position 47 is supposed
to be noticeable for entering of the substrate to the
channel and controlling substrate accessibility to the
binding pocket [35]. The leucine residues at position 86
could be effective for conformational changes of amino
acids near heme, resulting in alteration of the electron
transfer pathway to increase activity [36]. The substitu-
tion of phenylalanine 87 can directly interact with bound
substrates and affect the activity and stereo-selectivity or
regioselectivity of enzymes [37]. It is possible that the
substituted key amino acid in the wild type protein
might have altered CO difference spectra of M13 in
comparison with CYP450 BM3. These data indicate that
protein engineering was powerful method for enhance
the production of natural molecules. They also suggest
that one way to improve the activity of SaOMT2 toward
umbelliferone is by engineering via site-saturation muta-
genesis based on the structural model of substrate binding
site of the enzyme. Moreover, engineering of YjiC could
advance metabolic engineering by tailoring compounds
with high stereo-selectivity or regio-selectivity to achieve
high yields of desired molecules [38].
We also studied the biological activities of umbellifer-
one and its three derivatives as such antibacterial and
anticancer agents. Although the activities of four com-
pounds were tested against five bacteria, only herniarin
was effective against two Gram-positive bacteria B. sub-
tilis and S. aureus. This indicated that the methyl substi-
tution at the hydroxyl group of the C-7 position reduced
the water solubility and showed significant antibacterial
activity. The possible reason could explain that the en-
hanced lipophilicity of alkyl group leads to improving
the ability of herniarin to overcome cell membrane [39],
followed by coumarin-based inhibitors of bacteria repli-
cative DNA helicase [40]. Similar to bacterial activity,
among the four compounds, herniarin showed the most
potential anticancer activity against four tested cancer
cell lines. Although we accessed the activity of herniarin
and skimmin against AGS cell line for the first time,
these compounds could be used in further studies to re-
veal their exact mechanisms of action and their anti-
cancer effects in vivo. The previous study has reported
that umbelliferone have growth inhibitory effects on hu-
man cancer cell lines such as breast cancer (MCF-7) and
lung cancer (H727) [41]. Esculetin did not show activity
against the tested cell lines in this study. However, it has
anti-proliferative effects on G361 human malignant
melanoma [4] and U937 human leukemia cells [42] and.
These results provide the ability that modification of
umbelliferone might generate a promising anticancer
agent against various cancer cell lines.
Conclusion
In conclusion, the results demonstrate that both native
enzyme and engineered enzyme expressed in the whole
cell allow producing the precious compounds. As a result
we successfully produced three different molecules her-
niarin, esculetin and skimmin from umbelliferone using
engineered microbial cells. The employed fermentation
approach is cheaper than in vitro reaction and other
chemical synthesis methods. The biosynthesized mole-
cules were also accessed for their potential bioactivities
against different pathogens and cancer cell lines. The
present research suggests that the combinatorial biosyn-
thesis of different biosynthetic enzymes could rapidly
promote to a novel secondary metabolite.
Methods
Chemicals and reagents
Standard umbelliferone, δ–aminolevulinic acid hydrochlor-
ide (δ–ALA), SAM, deuterium oxide (D2O), and DMSO-d6
were purchased from Sigma-Aldrich (USA). UDP-α-D-
glucose, α-D-glucose 1-phosphate, and isopropyl-β-D-
thiogalactopyranoside (IPTG) were obtained from Gene-
chem (Korea). NADP oxidized form was provided from
Tokyo Chemical Industry Co., Ltd (Japan). HPLC-grade
acetonitrile and water were purchased from Mallinckrodt
Baker (Phillipsburg, NJ, USA). All other chemicals used
were of analytical grade.
Plasmids, microorganisms, and culture conditions
Plasmid pCW(Ori+)-mutant 13 (M13) carrying amino acid
substitution relative to wild type CYP450 BM3: M13
(R47L/L86I/F87V/L188Q) [43] and pET28a-YjiC were
constructed previously [24]. The sequence of previously
characterized S. avermitilis derived OMT [29] was cloned
using the first cloning site of pRSF-Duet vector to
make recombinant plasmid pRSF-Duet-SaOMT2. These
plasmids were transformed into E. coli BL21 (DE3)
(Stratagene, USA) using standard procedures. 100 μg/mL
of ampicillin and 50 μg/mL of kanamycin were used in LB
medium for protein expression and biotransformation
assay.
Enzyme expression and purification
E. coli BL21 (DE3) harboring recombinant pCW(Ori+)-P450
BM3 with pCW(Ori+)-mutant 13, pET28a-YjiC, and
pRSF-Duet-SaOMT2 were cultured in LB broth con-
taining appropriate antibiotics at 37 °C and 180 rpm for
6 h. 0.5 mM IPTG and 1 mM δ–ALA were used to ex-
pression of CYP450 BM3 and mutant 13 when cell
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optical density at 600 nm (OD600nm) reached 0.6. These
cells were further incubated for an additional 20 h at
28 °C before harvest. Furthermore, 0.5 mM IPTG was
used to induced for protein expression of pET28a-YjiC
and pRSF-Duet-SaOMT2 at 20 °C for 20 h. These cells
were harvested by centrifugation at 842 × g for 10 min
and suspended twice in 100 mM Tris–HCl (pH 7.6)
buffer containing 10% glycerol. Cells were suspended in
1 mL of the same buffer and lysed by sonication using a
Sonosmasher (Ultrasonic, Inc.). Following centrifugation
at 13,475 × g for 30 min at 4 °C, the protein fractions were
applied across 12% sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE). Amicon®Ultra-0.5 mL
100 K and 30 K devices (Merck, USA) were used to collect
soluble cytosolic fraction of CYP450 BM3, mutant 13, and
YjiC, SaOMT2, respectively. 100 mM Tris–HCl (pH 7.6)
buffer containing 10% glycerol was used to store solu-
tion fractions at −20 °C until next use. CYP450 BM3
protein content (nmol) = [(absorbance difference ×
1000)/91 mM−1cm−1] x dilution factor [44]. Protein
concentration was determined via Bradford method [45].
Enzyme essay
The reaction mixture was performed in 200 μL with
1 mM substrate. Hydroxylation reaction contained 50 μg/
mL CYP450 BM3 or mutant 13, 100 mM potassium phos-
phate buffer (pH 7.6), and 10 mM MgCl2.6H2O. The sam-
ple was pre-incubated at 37 °C for 15 min and the
reaction was initiated by the addition of NADPH regener-
ating system consisting of 10 mM glucose-6-phosphate,
0.5 U glucose-6-phosphate-dehydrogenase, and 0.5 mM
NADP+. Glucosylation reaction mixture was incubated
with 2 mM UDP-α-D-glucose, 10 mM MgCl2, 50 μg/mL
purified YjiC in 100 mM Tris–HCl buffer (pH 7.6).
Methylation reaction contained 50 μg/mL of purified
SaOMT2 and 10 mM MgSO4 with 2 mM SAM as methyl
donor in 100 mM Tris–HCl buffer (pH 7.6). Reactions
were incubated at 37 °C for 30 min. These reactions were
stopped by adding chilled methanol at twice volume
followed by vigorous shaking for 15 min. Mixtures were
then centrifuged at 13,475 x g for 30 min. The superna-
tants were used to HPLC-PDA and HR-QTOF ESI/MS.
The conversion percentage of each substrate was calcu-
lated through intergrated between substrate and product
peak area. A calibration standard was created using differ-
ent concentration of umbelliferone (10, 25, 50, 100, and
200 μg/mL).
Whole cell biotransformation
Seed cultures of E. coli BL21 (DE3) harboring recombin-
ant plasmids were prepared in 6 mL LB broth with ap-
propriate antibiotics followed by incubation at 37 °C
with shaking at 180 rpm for approximately 6 h. For
whole cell reaction of CYP450 mutant 13, 200 μL of
pre-inoculum was transferred into 250 ml flask contain-
ing 50 mL of different media (LB, TB, 1x M9 minimal
salt) with appropriate antibiotic and incubated at 37 °C.
When OD600 reached 0.8, the culture was induced with
1.0 mM IPTG and 0.5 mM δ-ALA and incubated at
28 °C for 12 h. Biotransformation of E.coli harboring
pET28a-YjiC and pRSF-Duet-SaOMT2 was induced by
0.5 mM IPTG at 20 °C for 12 h. 100 mM umbelliferone
was supplemented to the same samples. The culture
was incubated for an additional 12 h, collected, extracted
and analyzed.
Scale-up of whole cell biocatalyst system in a fermentor
Fermentation of three E.coli BL21 (DE3) recombinant
strains (CYP450 mutant 13, YjiC, and SaOMT2) was
carried out in 3-L media under optimal conditions as
described previously [34, 46]. The quantify of hydroxylated
and methylated production were taken every 12 h until
48 h. Likewise, glycosylated sample was taken every 3 h up
to 15 h. Then, culture broth was centrifuged. Finally, the
supernatant was extracted with twice volume of EtOAc.
Analytical methods
The culture broth was extract with double volume of
EtOAc (v/v = 2:1) using Soxhlet extractor. Soxhlet ex-
tractor was then kept still to separate two layers after the
mixture was shaken for 12 h at room temperature. A ro-
tary evaporator was used to dried EtOAc fraction. The
products were analyzed by HPLC-PDA using a reversed-
phase column (Mightysil RP–18 GP 250–4.6 (5 μm),
Kanto Chemical, Japan) at 330 nm. The binary mobile
phases were include solvent A [0.05% trifluroacetic acid in
HPLC-grade water] and solvent B (100% acetonitrile). The
total flow rate was kept at 1 mL/min for 30 min. The
percentages of solvent B used were as follows: 0–15%
(0–4 min), 45% (4–10 min), 75% (10–14 min), 90%
(14–20 min), 10% (20–25 min), 10% (25–30 min).
The compounds were purified by preparative HPLC
(Shimazu, Tokyo, Japan) with C18 column (YMC–Pack
ODS-AQ (250 × 20 mm I.D., 10 μm) linked to a UV de-
tector (330 nm). HR–QTOF ESI/MS analysis using an
ACQUITY UPLC® coupled with SYNAPT G2-S (Water
Corp., USA). For NMR analysis of the purified product,
compounds were dried, lyophilized, and dissolved in
DMSO-d6 and subjected to 700 MHz Bruker Biospin
NMR for one-dimensional 1H-NMR, 13C-NMR, and
two-dimensional HMBC analyses.
Solubility study
50 μM of umbelliferone, esculetin, skimmin and herniarin
were separately dissolved in 200 μL phosphate-buffered
saline (PBS) at pH 7.6. The mixtures were vortexed for
30 min and centrifuged at 13,475 x g for 15 min. The
supernatants were collected and filtered through 0.45-μm
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syringe filters. Subsequently, aliquots (20 μL) were ana-
lyzed by HPLC-PDA at 330 nm. The concentrations of all
compounds dissolved in PBS were determined by regres-
sion equations.
Antibacterial activity
Three Gram-positive bacteria (Staphylococcus aureus subsp.
aureus KCTC 1916, Bacillus subtilis KACC 17047, and
Micrococcus luteus KACC 13377) and two Gram-negative
bacteria (Pseudomonas aeruginosa KACC 10232 and
Enterobacter cloaceae subsp. disolvens KACC 13002)
were used to test antibacterial activity of umbelliferone
and its derivatives. The paper disc diffusion assay on
Mueller-Hinton agar (MHA) plate were carried out. Inoc-
ula containing 107 colony forming units (CFU)/mL were
spread onto MHA plates. 10 μL of 100 mM compounds
were placed on the surface of inoculated agar plates
through sterile filter paper discs. The samples were then
incubated at 37 °C for 12 h. The zone of inhibition diam-
eter was measured in millimeter [47].
Anticancer activities
Four cencer cell lines (B16F10, AGS, HeLa, and
HepG2) grown in Roswell Park Memorial Institute
1640 medium containing 10% fetal bovine serum
(FBS) (Invitrogen, USA) were applied to test antican-
cer activities of umbelliferone and its derivatives. All
cells were maintained at 37 °C in a humidified 5%
CO2 incubator. For cell growth assay, cells seeded at
2 x 103 cell/well in 96-well plates (SPL Life Sciences,
Korea) were treated with each compound after serial
dilution (400 μM, 200 μM, 100 μM, 50 μM, 25 μM,
12.5 μM) for 72 h. Cell viability was measured using
MTT colorimetric assay [48].
Statistical analysis
Values are mean ± standard deviation (SD). SD was calcu-
lated from the results of three independent experiments.
Differences with p value < 0.05 were indicated a statisti-
cally significant.
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